Neuphoria Therapeutics Inc.
Description
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
About
CEO
Dr. Spyridon Papapetropoulos M.D., Ph.D.
Employees
8
Instrument type
Depositary Receipt
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
200 Greenhill Road, Eastwood, SA 5063, Australia
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Sep 29, 2025 | — | — | — | — |
| Mar 13, 2025 | — | — | — | — |
Earnings estimate
|
Current Year
(Jun 2025)
|
Next Year
(Jun 2026)
|
|||
|---|---|---|---|---|
| Number of analysts | — | — | 0 | 0 |
| Average estimate | — | — | 0.00 | 0.00 |
| Low estimate | — | — | 0.00 | 0.00 |
| High estimate | — | — | 0.00 | 0.00 |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr.
—
Current year (Jun 2025)
—
Next year (Jun 2026)
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total reported revenue | — | — | 287,980 | — | 32,062 |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | 32,062 |
| Operating expense | |||||
| Research & development | 9.42M | 13.07M | 17.48M | 4.33M | 4.00M |
| Selling general and admin | 8.47M | 8.91M | 8.37M | 4.24M | 3.33M |
| Other operating expenses | -95,215 | -422,742 | -2.24M | 386,743 | -1.11M |
| Operating income | -17.80M | -21.56M | -23.31M | -8.96M | -6.19M |
| Non operating interest income | |||||
| Income | 220,097 | 323,158 | 10,778 | 4,324 | 40,106 |
| Expense | — | 14,084 | 29,352 | 882,324 | 1.23M |
| Other income expense | 2.00M | -283,775 | -628,474 | 3.36M | 3.28M |
| Pretax income | -15.58M | -21.52M | -23.98M | -6.68M | -4.14M |
| Tax provision | -87,320 | -139,174 | -209,521 | -140,820 | -142,654 |
| Net income | -15.49M | -21.38M | -23.77M | -6.53M | -4.89M |
| Basic EPS | -1.80 | -3.60 | -2.48 | -1.51 | -1.53 |
| Diluted EPS | -1.80 | -3.60 | -2.48 | -1.51 | -1.53 |
| Basic average shares | 9.99M | 12.96M | 11.94M | 6.88M | 5.10M |
| Diluted average shares | 9.99M | 12.96M | 11.94M | 6.88M | 5.10M |
| EBITDA | -19.13M | -20.61M | -22.10M | -7.73M | -4.37M |
| Net income from continuing op. | -15.49M | -21.38M | -23.77M | -6.53M | -4.89M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 27.65M | 28.56M | 71.34M | 40.77M | 23.68M |
| Current assets | |||||
| Cash | — | 18.25M | 36.66M | 21.41M | 3.15M |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 12.61M | 12.10M | 36.66M | 21.41M | 3.15M |
| Other short term investments | — | — | — | 327,312 | — |
| Accounts receivable | — | — | — | 144,771 | 12,061 |
| Other receivables | 96,154 | 416,072 | 7.39M | 844,349 | 28,678 |
| Inventory | — | — | — | — | — |
| Prepaid assets | 458,765 | 797,478 | 1.60M | 646,745 | 532,205 |
| Restricted cash | — | — | — | 327,312 | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | — | — | — | 699,427 | 2.01M |
| Non current assets | |||||
| Properties | 216,975 | 524,775 | — | 1.78M | 1.04M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 47,716 | 47,759 | 78,686 | 80,207 | 943,899 |
| Construction in progress | — | — | — | — | — |
| Leases | — | 854,500 | 933,413 | 1.78M | — |
| Accumulated depreciation | -45,722 | -45,237 | -275,277 | -1.21M | -1.26M |
| Goodwill | 22.85M | 23.52M | 38.86M | 26.11M | 25.77M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 5.47M | 6.13M | 10.75M | 7.47M | 8.08M |
| Investments and advances | — | — | — | 119,000 | 436,174 |
| Other non current assets | 78,826 | 78,897 | 129,989 | 89,409 | — |
| Total liabilities | 10.16M | 6.55M | 9.17M | 5.01M | 14.97M |
| Current liabilities | |||||
| Accounts payable | 2.24M | 1.44M | 1.70M | 772,933 | 866,778 |
| Accrued expenses | 1.10M | 1.11M | 1.34M | 590,285 | — |
| Short term debt | 155,110 | 147,080 | 174,819 | 130,896 | 4.09M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | — | 457,017 | 447,121 | 279,449 | 267,170 |
| Other current liabilities | 328,881 | 62,572 | — | — | — |
| Non current liabilities | |||||
| Long term debt | 117,628 | 239,835 | 582,859 | 521,144 | 4.32M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 963,540 | 1.10M | 1.96M | 1.38M | 1.51M |
| Derivative product liabilities | 4.66M | — | — | — | — |
| Other non current liabilities | 590,648 | 2.47M | 2.95M | 1.32M | 3.42M |
| Shareholders equity | |||||
| Common stock | — | — | 237.80M | 142.90M | 101.80M |
| Retained earnings | -177.98M | -162.48M | -189.31M | -115.74M | -102.30M |
| Other shareholders equity | -3.01M | -3.06M | 13.68M | 8.60M | 9.22M |
| Total shareholders equity | 17.49M | 22.01M | 62.17M | 35.76M | 8.71M |
| Additional paid in capital | 198.48M | 297.82M | — | — | — |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||
| Net Income | -15.49M | -21.38M | -23.77M | -6.53M | -4.89M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation | 662,991 | 663,192 | 1.21M | 1.28M | 1.68M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 814,808 | 1.35M | 3.09M | 983,011 | 38,035 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | -1.75M | 707,749 | 1.01M | -1.83M | -3.10M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Accounts Receivable | 299,203 | 4.14M | -6.37M | 1.52M | 2.71M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Accounts Payable | 804,371 | 594,165 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -265,284 | -126,651 | -820,387 | -247,187 | -23,627 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Cash Flow | -14.93M | -14.06M | -25.64M | -4.83M | -3.59M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Activities | ||||||||||||||||||||||||||
| Capital Expenditures | — | — | 189,573 | 25,670 | 176,360 | -69,282 | -358,109 | -190,199 | -146,897 | -649,080 | -203,926 | -157,585 | 5.87M | -81,104 | -36,468 | -86,096 | -369,127 | -114,500 | -133,165 | -325,032 | -88,888 | -29,176 | -864,653 | -221,399 | -324,891 | — |
| Net Intangibles | — | — | — | — | — | — | — | — | 51,218 | — | — | — | — | — | -2,542 | -2,958 | — | — | — | -1.61M | — | — | — | — | -52,672 | — |
| Net Acquisitions | — | — | — | — | -692,611 | — | — | — | — | -300,001 | — | 233,880 | — | — | — | — | — | — | 11,794 | -66,733 | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | -89,007 | -35,849 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Sale of Investments | — | — | 475,870 | — | 377,915 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | — | — | 665,443 | -63,337 | 167,881 | -59,527 | -358,109 | 1.01M | 1.09M | -8,474 | 363,403 | -1.21M | 7.00M | 326,644 | 431,401 | 200,725 | 300,308 | -114,500 | -121,371 | -391,765 | -88,888 | -29,176 | -864,653 | -221,399 | -324,891 | — |
| Financing Activities | ||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | 1.75M | 76,845 | 4.32M | 9.73M | 319,862 | 79,938 | 667,656 | — | 21,839 | 21,640 | 143,511 | 339,270 | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | -105,935 | -190,307 | -8.92M | -5.69M | -3.73M | -113,556 | -1.79M | -603,418 | -512,064 | -131,180 | -167,754 | -2.36M | -517,418 | -340,313 | -355,650 | -440,889 | -307,145 | -266,118 | -63,982 | — | — | — | — | — | — |
| Other Financing Charges | — | -1.13M | -6.25M | -312,164 | -226,678 | -294,400 | — | — | — | — | — | — | — | — | — | — | — | — | — | -222,940 | -368,005 | -18,974 | -87,500 | -185,527 | -364,763 | — |
| Financing Cash Flow | 10.11M | 2.63M | 29.49M | 23.29M | -3.73M | 2.63M | 1.94M | -1.60M | 24.79M | 9.43M | 573,847 | 14.36M | -1.59M | 12.92M | 12.38M | 2.68M | -198,456 | 12.32M | -266,118 | 4.59M | 3.49M | 794,226 | 1.67M | 3.89M | 3.27M | 93,456 |
| Other Cash Details | ||||||||||||||||||||||||||
| End Cash Position | 12.69M | 12.18M | 36.66M | 21.41M | 3.15M | 9.79M | 18.31M | 32.95M | 33.94M | 20.34M | 9.89M | 20.49M | 17.74M | 17.16M | 10.72M | 3.84M | 6.01M | 10.87M | 3.51M | 6.87M | 6.08M | 4.09M | 4.86M | 5.02M | 2.71M | 57,409 |
| Income Tax Paid | — | — | — | — | — | — | — | 65,677 | — | — | — | -293,534 | -565,811 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | 726,420 | 1.34M | 1.93M | 1.93M | 1.95M | 1.70M | 743,222 | 87,236 | 78,198 | 64,450 | 305,925 | 247,850 | 283,047 | 313,434 | 305,029 | 332,243 | 321,024 | 231,840 | 302,411 | 72,375 | — | 5,893 | — |
| Free Cash Flow | -14.68M | -14.64M | -23.77M | -5.67M | -2.69M | -10.98M | -15.38M | -1.30M | -11.62M | 3.14M | -12.36M | -9.33M | -4.77M | -9.68M | -6.07M | -4.11M | -6.70M | -5.46M | -2.92M | -4.47M | -2.24M | -2.54M | -2.51M | -1.55M | -1.22M | -105,472 |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|
Article
Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Neuphoria Therapeutics Inc. (NEUP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Feb 6, 2025
Article
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited's proposed re-domiciliation from Australia to the United States, under which Neuphoria will become the ultimate parent company of Bionomics Limited, has been implemented today, December 23, 2024 New York time (December 24, 2024 Sydney time).
Dec 23, 2024
